Ann: Clinical milestones for 2024 & 2023 successes highlighted, page-17

https://medicalxpress.com/news/2024-03-fda-car-cell-therapy-adults.html

Another CAR-T approval. First therapy for adults with leukemia or lymphoma, another bar set.

Accelerated approval was based on response rate and duration of response.

"The results of the phase 1/2 trial of 89 patients indicated a complete response rate of 20 percent with Breyanzi treatment"

"The overall response rate was 45 percent, with a median duration of response of 35.3 months. Across patients treated with Breyanzi who achieved a complete response, the minimal residual disease negativity rate was 100 percent in the blood and 92.3 percent in the bone marrow"